Stifel Terminates Coverage On Oncolytics Biotech Due To Reallocation Of Resources
In a report published Monday, Stifel analyst Brian Klein terminated coverage on Oncolytics Biotech (NASDAQ: ONCY).
In the report, Stifel noted, "Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be used as an indicator for the company going forward."
Oncolytics Biotech closed on Friday at $0.42.
Latest Ratings for ONCY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2021 | HC Wainwright & Co. | Initiates Coverage On | Buy | |
| May 2020 | RBC Capital | Maintains | Outperform | |
| Sep 2013 | Needham | Initiates Coverage On | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Brian Klein StifelAnalyst Color Termination Analyst Ratings
